Safety and efficacy of BCMA CAR-T <i>vs.</i> bispecific antibodies in patients with relapsed multiple myeloma: a systematic review and meta-analysis

2025/08/13 by Hayley Vandenboom, Othman Salim Akhtar, Othman Akhtar +7
Immunology and Microbiology · Medicine · #Biosimilars and Bioanalytical Methods #CAR-T cell therapy research #Monoclonal and Polyclonal Antibodies Research

paper · pdf · doi:10.3324/haematol.2025.288174

openalex publication_date 2025/08/13 · openalex created_date 2025/08/17 · openalex updated_date 2026/07/29

Abstract

Not available.

Related

• The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
• International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma
• Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels
• T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
• Feasibility of post-induction consolidation with BCMA CAR-T cell therapy in newly diagnosed multiple myeloma not proceeding to ASCT: A preliminary case series